Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter

被引：6
|
作者：
Businello, Gianluca [1 ]
Angerilli, Valentina [1 ]
Lonardi, Sara [2 ]
Bergamo, Francesca [2 ]
Valmasoni, Michele [3 ]
Farinati, Fabio [3 ]
Savarino, Edoardo [3 ]
Spolverato, Gaya [3 ]
Fassan, Matteo [1 ,2 ]
机构：
[1] Univ Padua, Dept Med DIMED, Padua, Italy
[2] Ist Ricovero & Cura Carattere Sci IRCCS, Veneto Inst Oncol, Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol DISCOG, Padua, Italy
来源：
UPDATES IN SURGERY | 2023年 / 75卷 / 02期
关键词：
Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Biomarkers; Immunohistochemistry; ADVANCED GASTRIC-CANCER; TYROSINE KINASE INHIBITOR; FGFR2 GENE AMPLIFICATION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; HER2; STATUS; PHASE-II; MICROSATELLITE INSTABILITY; GASTROESOPHAGEAL CANCER;
D O I：
10.1007/s13304-022-01330-5
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
引用
收藏
页码：291 / 303
页数：13
相关论文
共 50 条
  • [41] Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction
    Markus Menges
    Thomas Hoehler
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 29 - 38
  • [42] Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting
    Garcia Grove, C.
    Gallego Jimenez, I.
    Martinez Bernal, G.
    Miras Rodriguez, I.
    Limon Miron, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S119 - S119
  • [43] EVALUATION OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY FOR RESECTABLE ADENOCARCINOMA OF THE ESOPHAGUS OR GASTROESOPHAGEAL JUNCTION
    AJANI, JA
    ROTH, JA
    RYAN, B
    MCMURTREY, M
    RICH, TA
    JACKSON, DE
    ABBRUZZESE, JL
    LEVIN, B
    DECARO, L
    MOUNTAIN, C
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1231 - 1238
  • [44] Oligometastatic Gastroesophageal Adenocarcinoma: Molecular Pathophysiology and Current Therapeutic Approach
    Jung, Jin-On
    Nienhueser, Henrik
    Schleussner, Nikolai
    Schmidt, Thomas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [45] Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
    Schulz, Christoph
    Stintzing, Sebastian
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2175 - 2177
  • [46] A Review of Type III Gastroesophageal Junction Adenocarcinoma and the Importance of Early Detection of Gastric Cancer
    Jadhav, Alisha
    Ayyat, Mumen
    Serafini, Francesco M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [47] Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States
    Afsaneh, Barzi
    Lisa, Hess
    Zhu Yajun
    Astra, Liepa
    Fang Yun
    Craig, Kuder
    Julie, Beyrer
    Joseph, Chao
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions
    Richards, Donald A.
    Boehm, Kristi A.
    Anthony, Stephen P.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) : 1059 - 1068
  • [49] Multimodal Therapy for Gastric Carcinoma and gastroesophageal junction Adenocarcinoma - ECF vs. FLOT
    Schroeder, W.
    Bruns, C. J.
    CHIRURG, 2017, 88 (06): : 540 - 540
  • [50] A proactive financial navigation intervention in patients with newly diagnosed gastric and gastroesophageal junction adenocarcinoma
    Ari Bell-Brown
    Talor Hopkins
    Kate Watabayashi
    Karen Overstreet
    Anthony Leahy
    Erin Bradshaw
    Kathleen Gallagher
    Jennifer Obenchain
    Amber Padron
    Beth Scott
    Brooke Flores
    Veena Shankaran
    Supportive Care in Cancer, 2024, 32
12345